Mustika Ratu Tbk (MRAT)
Jakarta Exchange · Indonesia · prices in IDR · close of 23 Oct 2026
Key indicators
| Last close | IDR 400.00 |
|---|---|
| 52-week range | 340.00 – 755.00 |
| Return, 1 month / 3 months | +9.9% / −9.1% |
| Return, 1 year / 3 years | −7.0% / +5.8% |
| Trend | Below its 200-day average |
| RSI (14) | 54 |
| Volatility (1 year) | 55.4% |
| Worst drawdown (1 year) | -50.8% |
| Average daily value traded | 244.42M IDR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Mustika Ratu Tbk is an Indonesian company that makes cosmetics, skincare products and traditional herbal remedies known as jamu. Its range covers beauty treatments, body care and health drinks inspired by Indonesian herbal traditions. The company serves consumers in Indonesia and also exports some products to overseas markets. It is based in Jakarta and sells through retailers, distributors and its own outlets, drawing on local plant ingredients and traditional recipes in the products it develops and markets.
On this site Mustika Ratu Tbk appears as a stock on the Jakarta Exchange (Indonesia), code MRAT, with prices in Indonesian rupiah (IDR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Mustika Ratu Tbk (MRAT) trades on the Jakarta Exchange in Indonesia. It last closed at IDR 400.00 on 23 October 2026.
Its price-based Market X-Ray is 47 out of 100 (a weak price profile), ranking 507 of 923 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 7.0% and over the last three months it fell 9.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Jakarta Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 48 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -6.7% | ||
| From 52-week high | -44.1% | ||
| Momentum | 49 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -9.1% | ||
| 6-month return | -3.4% | ||
| 12-month return, skipping the last month | -15.3% | ||
| Stability (higher is calmer) | 55 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 55.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -50.8% | ||
| Liquidity | 31 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 244.42M IDR | ||
| Zero-volume days | 3.3% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +5.8% |
|---|---|
| 1 month | +9.9% |
| 3 months | −9.1% |
| 6 months | −3.4% |
| 1 year | −7.0% |
| 3 years | +5.8% |
| 5 years | +66.7% |
Signals
| 50-day / 200-day average | 394.24 / 428.57 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 25.11 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Jakarta Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.